0% Survival Rate Increase! AstraZeneca's Precision Medicine Dato-DXd Trial Fails Miserably, Investor Confidence Crumbles

AstraZeneca's experimental precision drug did not significantly improve overall survival for patients in the trial, the company said in a detailed trial of its lung cancer treatment published on Monday. A report released by Astrazeneca at the World Lung Cancer Congress in San Diego detailing the results of the TROPION-Lung01 trial made clear that overall survival from the trial "did not reach statistical significance." The results certainly disappointed investors and analysts who had been closely watching the late-stage trial and had high hopes that the drug, called Dato-DXd, could become another blockbuster drug for Astrazeneca.

The main aim of the trial was to compare the efficacy of Astrazeneca's experimental drug with conventional chemotherapy. The trial involved patients whose non-small cell lung cancer had returned after one or two previous treatment attempts. The patients were randomly assigned to receive either Astrazeneca's drug or chemotherapy to assess which treatment was more effective.

Some preliminary data related to the trial had already had a negative impact on Astrazeneca's share price. In July 2023, after the company released interim data for progression-free survival (PFS), the stock price fell 8%. Later in the year, when the company released more PFS data related to the trial, the stock price fell again. Nevertheless, overall survival, as another important criterion for the efficacy of cancer drugs, is still receiving much attention.

Dato-DXd belongs to a high-profile class of antibody drug conjugators (ADCs), which consist of a monoclonal antibody that recognizes and targets tumor cells in combination with a cell-killing chemotherapy payload. The drug was developed with joint support from Japanese pharmaceutical company Daiichi Sankyo (stock code 4568.T), which jointly developed the drug under the new label. Although the current trial results are not satisfactory, Astrazeneca and Otsuka will continue to focus on the potential of this drug and may further explore its efficacy in future clinical trials.